Fly News Breaks for December 31, 2019
Dec 31, 2019 | 06:44 EDT
Credit Suisse analyst Martin Auster keeps his Outperform rating and $40 price target on Insmed ahead of its Phase 2 WILLOW Study results for INS1007 expected in the "next few weeks", saying the risk-reward skew on the program looks "favorable". With clinicaltrials.gov having marked the study targeting non-cystic fibrosis bronchiectasis as "completed", the analyst sees a "solid optionality" on the readout, and if successful, estimates the drug's potential to generate peak sales of up to $1B. If the outcome is a "clear win", Auster expects a share upside of $8 to $10 for Insmed.
News For INSM From the Last 2 Days
There are no results for your query INSM